Jefferies Upgrades Edwards Lifesciences (EW) to Buy

Jefferies analyst Matthew Taylor upgraded Edwards Lifesciences (NYSE: EW) from Hold to Buy with a price target of $98.00 (from $80.00).

The analyst comments: "We are upgrading shares of EW to Buy on the back of a stellar TCT and support from high-frequency data suggesting TAVR growth is accelerating. P3 7-year data lends confidence to the durability of TAVR and could increase implantation rates in low-risk pts. Plus, better Evoque real-world data was a positive surprise at TCT and could juice that market, while TMVR data should support approval and complete EW's TMTT 'toolbox'."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $82.19 yesterday.

You May Also Be Interested In

• U.S. officials have told CBS News that there are no "new" or novel negotiations planned
• Barclays: 'we'll be curious to hear what Energizer has seen and how 2H expectations have evolved'
• Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?